TheranosticTrials.org

Clinical Trial · NCT02899325

FDGal PET/CT to Detect Hepatocellular Carcinoma

Overview

Liver cancer is one of the leading causes of cancer death among Asian men. If diagnosed early the disease is treatable with surgery. Current conventional imaging modalities have limitations to early detection. This study proposes to use 18F-FGal and 18F-FDG PET/CT scans to compare the clinical efficacy of diagnosing hepatocellular carcinoma (a type of liver cancer) using these PET/CT scans.

Sponsor

British Columbia Cancer Agency

Contacts

Francois Benard, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02899325

Drug / Compound

FDGal

Isotope(s):
Target(s):
  • Galactokinase
Ligand Class: Small Molecules

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Patient who accepts to enter the study by signing written informed consent.
  • Patient with performance status ≤ 2 Eastern Cooperative Oncology Group (ECOG).
  • Patient with cirrhosis or chronic liver disease suspected to have at least 1 hepatic nodule larger than 1 cm in diameter detected by conventional image (US, CT, MRI).
  • * Male or female, age ≥ 19 years of age.
  • Hepatic nodule is defined as any one of the following conditions: suspicious hepatocellular carcinoma, benign tumor such as hemangioma, adenoma or focal nodular hyperplasia, possible metastatic lesions from other primary malignancy.

Exclusion

  • Female patient who is pregnant, lactating or planning to become pregnant during the study.
  • * Patient has serious allergic history or known allergy to 18F-FDGal or 18F-FDG.
  • Patient has been diagnosed with multiple malignancies.
  • Patient has received therapy for aforementioned diagnosis before the PET scans
  • Patient with known (proven) metastases from a prior malignancy